Cabbar, Ayca TurerYildirim, ErsinCalbayram, Ozge GuzelburcSimsek, Mustafa A.Altay, ServetOzcan, Kazim S.Degertekin, M. Muzaffer2024-06-122024-06-1220231995-18921680-0745https://doi.org/10.5830/CVJA-2023-046https://hdl.handle.net/20.500.14551/24047Objective: The aim of this study was to determine adiponectin and copeptin levels that might be prognostic for cardiovascular mortality (CvsM) in ST-segment elevation myocardial infarction (STEMI) patients who had percutaneous coronary intervention (PCI).Methods: Patients who underwent PCI between November 2010 and April 2011 were enrolled and followed for more than eight years. The baseline, demographic and angiographic findings, in-hospital follow up, laboratory results including adiponectin and copeptin levels, and echocardiographic data of the patients were evaluated.Results: There were 78 males and 20 females. The CvsM rate was 26.66% at 112 months of follow up. Some factors were significantly related to CvsM and adiponectin level was an independent predictor of mortality. A cut-off value of >= 8 950 ng/ml for adiponectin and >= 7.41 ng/ml for copeptin was related to a 3.01-and 2.83-times higher CvsM risk, respectively.Conclusion: Adiponectin level was a predictor for CvsM. Higher levels of adiponectin and copeptin could predict a higher risk of CvsM in STEMI patients.en10.5830/CVJA-2023-046info:eu-repo/semantics/closedAccessST-Segment Elevation Myocardial InfarctionMortalityAdiponectinCopeptinAll-Cause MortalityPlasma AdiponectinHeart-FailureSerum AdiponectinPrognostic-FactorPrimary PciAssociationEventsStemiPredictionArticleN/AWOS:00108441830000137906447